Bicara Therapeutics Revenue and Competitors

Boston, MA USA

Location

$313M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Bicara Therapeutics's estimated annual revenue is currently $5.4M per year.(i)
  • Bicara Therapeutics's estimated revenue per employee is $77,500
  • Bicara Therapeutics's total funding is $313M.

Employee Data

  • Bicara Therapeutics has 70 Employees.(i)
  • Bicara Therapeutics grew their employee count by 59% last year.

Bicara Therapeutics's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Chief Financial OfficerReveal Email/Phone
3
CMO, Bicara TherapeuticsReveal Email/Phone
4
Chief Legal OfficerReveal Email/Phone
5
Chief Legal OfficerReveal Email/Phone
6
SVP, Global Head Technical Operations and Supply ChainReveal Email/Phone
7
VP, Head Regulatory AffairsReveal Email/Phone
8
VP, Head Clinical OperationsReveal Email/Phone
9
SVP, R&D Strategy & OperationsReveal Email/Phone
10
Head Pharmacovigilance & Drug SafetyReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$12.7M82-45%$107.3MN/A
#2
$0.2M1-50%N/AN/A
#3
$6.2M4021%N/AN/A
#4
$42.2M2184%$165MN/A
#5
$14.6M94-37%$312.8MN/A
#6
$0.3M2-67%N/AN/A
#7
$235M366-5%$340.9MN/A
#8
$56M289-7%$7.6MN/A
#9
$4.7M6136%N/AN/A
#10
$2M138%N/AN/A
Add Company

What Is Bicara Therapeutics?

Bicara Therapeutics is a clinical-stage company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of tumor modulators. The company's dual-action biologics are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy. For more, please visit: bicara.com.

keywords:N/A

$313M

Total Funding

70

Number of Employees

$5.4M

Revenue (est)

59%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.6M70-12%N/A
#2
$7.5M708%N/A
#3
$15M70-5%N/A
#4
$9.1M709%N/A
#5
$20M70-35%$17.7M